antibodies against fbxo11 (Proteintech)
Structured Review

Antibodies Against Fbxo11, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against fbxo11/product/Proteintech
Average 92 stars, based on 6 article reviews
Images
1) Product Images from "Cullin‐associated and neddylation‐dissociated 1 regulate reprogramming of lipid metabolism through SKP1‐Cullin‐1‐F‐box FBXO11 ‐mediated heterogeneous nuclear ribonucleoprotein A2/B1 ubiquitination and promote hepatocellular carcinoma"
Article Title: Cullin‐associated and neddylation‐dissociated 1 regulate reprogramming of lipid metabolism through SKP1‐Cullin‐1‐F‐box FBXO11 ‐mediated heterogeneous nuclear ribonucleoprotein A2/B1 ubiquitination and promote hepatocellular carcinoma
Journal: Clinical and Translational Medicine
doi: 10.1002/ctm2.1443
Figure Legend Snippet: Cullin‐associated and neddylation‐dissociated 1 (CAND1) functions by regulating the SCFFBXO11 complex to recruit hnRNPA2B1. (A) A coimmunoprecipitation (co‐IP) experiment detected binding between CAND1 and CUL1. (B) CUL1 knockdown partially reversed the CAND1 overexpression‐induced promotion of cell invasion. (C) CUL1 knockdown reduced colony formation in CAND1 overexpressing HCC‐LM3 cells. (D) CCK8 assay showing that CUL1 knockdown reduces the proliferation of CAND1‐overexpressing cells. (E) BODIPY staining showed that lipid accumulation clearly decreased in the CUL1 knockdown group. (F) CUL1 knockdown partially reversed the CAND1 overexpression‐induced increase in intracellular triglycerides and cholesterol. (G) Relative quantitative mass spectrometry (MS)‐based proteomic analysis. (H) A co‐IP experiment was performed to detect binding between CUL1 and different F‐box proteins. (I) A co‐IP experiment was performed to detect binding between FBXO11 and hnRNPA2B1, and binding between hnRNPA2B1 and other F‐box proteins. (J) GST pull‐down assay. (K) A co‐IP experiment was performed to detect binding between HA‐FBXO11 and Flag‐hnRNPA2B1. (L) FBXO11 immunolabeling shows colocalization with hnRNPA2B1. All cellular experiments were run in triplicate and repeated three times. p < .05(*), p < .01(**) or p < .001(***).
Techniques Used: Co-Immunoprecipitation Assay, Binding Assay, Knockdown, Over Expression, CCK-8 Assay, Staining, Mass Spectrometry, Pull Down Assay, Immunolabeling
Figure Legend Snippet: hnRNPA2B1 mediates cullin‐associated and neddylation‐dissociated 1 (CAND1) function that was antagonized by FBXO11. (A) Protein expression was assessed by a western blot of cells with CAND1 expression knocked down. (B) The expression of hnRNPA2B1, FASN, ACC1 and ACLY increased when CAND1 was overexpressed. (C) Protein expression was assessed with cells in FBXO11 expression knocked down. (D) Protein expression in cells with FBXO11 expression knocked down. (E) A Cell Counting Kit‐8 (CCK‐8) assay suggesting that hnRNPA2B1 overexpression reverses the inhibition of cell proliferation mediated by CAND1 knockdown. (F) Colony formation assays demonstrate that overexpression of hnRNPA2B1 partially reversed the suppressed proliferation induced by CAND1 knockdown. (G‐H) CAND1 expression knockdown effects on cell migration and invasion were partially reversed by hnRNPA2B1 overexpression. (I) CAND1 knockdown downregulates hnRNPA2B1 expression, which was reversed by shFBXO11. (J) CAND1 promotes lipid synthesis, which is reversed by FBXO11. (K) CAND1 overexpression upregulates hnRNPA2B1 expression, which is reversed by overexpression of FBXO11. All cellular experiments were run in triplicate and repeated three times. p < .05(*), p < .01(**) or p < .001(***).
Techniques Used: Expressing, Western Blot, Cell Counting, CCK-8 Assay, Over Expression, Inhibition, Knockdown, Migration
Figure Legend Snippet: Cullin‐associated and neddylation‐dissociated 1 (CAND1) suppresses SCFFBXO11 complex‐mediated hnRNPA2B1 ubiquitination and degradation. (A) FBXO11 overexpression accelerates hnRNPA2B1 degradation. (B) FBXO11 expression knockdown decelerates hnRNPA2B1 degradation. (C) Knocking down CAND1 expression accelerates hnRNPA2B1 degradation. (D) MG132 significantly increases hnRNPA2B1 protein levels. (E) FBXO11‐induced degradation of hnRNPA2B1 is reversed by MG132 treatment. (F) The ubiquitination of hnRNPA2B1 is promoted by CAND1 expression knockdown. (G) The ubiquitination of hnRNPA2B1 is inhibited by CAND1 overexpression. (H) shRNA knockdown of FBXO11 expression levels decreased hnRNPA2B1 ubiquitination. (I) Overexpression of FBXO11 increased hnRNPA2B1 ubiquitination. (J) FBXO11 promotes hnRNPA2B1 ubiquitination in 293T cells. (K) hnRNPA2B1 protein levels are regulated by FBXO11 in a dose‐dependent manner. (L) Ubiquitination levels of hnRNPA2B1 are increased by FBXO11 in a dose‐dependent manner. (M) hnRNPA2B1 ubiquitination is regulated by CAND1 in a dose‐dependent manner. The experiments were dependently repeated three times.
Techniques Used: Ubiquitin Proteomics, Over Expression, Expressing, Knockdown, shRNA
Figure Legend Snippet: FBXO11 directly binds to and promotes K27‐ and K48‐linked ubiquitination of hnRNPA2B1. (A) Domain architectures in FBXO11 proteins. (B) FBXO11 and mutant FBXO11 were overexpressed, and ubiquitination of hnRNPA2B1 was detected. (C, D) A co‐IP experiment was performed to detect the binding of hnRNPA2B1 to FBXO11 and mutant FBXO11. (E) Domains shown in the structure diagram of hnRNPA2B1. (F) Diagrammatic representation showing hnRNPA2B1 and its truncated forms. (G) A co‐IP experiment was performed to detect the binding of FBXO11 with hnRNPA2B1 and its truncated forms. (H) The degradation rate of mutant hnRNPA2B1 is not affected by FBXO11. (I) When FBXO11 was overexpressed, ubiquitination levels of wild‐type hnRNPA2B1 and mutant hnRNPA2B1 protein levels were detected. Compared with that of wild‐type hnRNPA2B1, the ubiquitination of mutant hnRNPA2B1 was decreased. (J) FBXO11 specifically promoted the addition of K27‐ and K48‐linked ubiquitin to hnRNPA2B1. (K) K27R and K48R ubiquitin could induce the ubiquitination of hnRNPA2B1. (L) Mutant K27 and K48 ubiquitin does not increase the extent of hnRNPA2B1 ubiquitination. The experiments were dependently repeated three times.
Techniques Used: Ubiquitin Proteomics, Mutagenesis, Co-Immunoprecipitation Assay, Binding Assay
Figure Legend Snippet: AAV‐shCAND1 effectively inhibits hepatocellular carcinoma (HCC) as a gene therapy. (A) Images of the patient‐derived xenograft (PDX) mice. (B) Plot showing tumour volume over time in the PDX mouse model. (C) Statistics of body weights of the PDX mice. (D) Interstitial fluid pressure (IFP) of tumours in PDX models. (E) Survival curve of the mice bearing PDX tumours. (F) Images of tumours in the PDX models. (G) Statistics of tumour weight of PDX mice. (H) Immunohistochemical staining of CAND1, hnRNPA2B1, FASN, ACC1 and ACLY, and oil red O staining. (I) Representative images of mouse livers with tumours induced by myr‐AKT/NRASV12 and immunohistochemical staining of fatty acid synthesis‐related proteins and oil red O staining of HCC mouse model tumour tissue. (J) IHC of tumour tissue from HCC patients. (K) Diagram of the molecular mechanisms underlying the CAND1‐SCF FBXO11 ‐hnRNPA2B1 axis. p < .05(*), p < .01(**) or p < .001(***).
Techniques Used: Derivative Assay, Immunohistochemical staining, Staining
Figure S2 . Images were taken on an AxioImager Z2 with Apotome 3 with a 40× objective. Scale bar, 20 μm. (F) Quantification of PAX6-positive cells among NPCs shows comparable levels of PAX6-positive cells for WT, KO, and HET cells. Quantification for individual lines can be found in
Figure S5 . (C) Integration of GO term analysis of FBXO11-deficient human neuron and Drosophila head transcriptome analysis. The top five biological processes enriched in GO term analysis of human neurons are shown in black. The enrichment of these processes in Fbxo11-deficient Drosophila heads are shown in green. (D) Stacked bar chart grouping genes expressed in FBXO11 KO neurons based on their differential gene expression and colored by corresponding expression changes during neuronal differentiation in a publicly available dataset on gene expression during differentiation from hIPSC to neurons. Increasing expression during differentiation is marked in green, and decreasing expression during differentiation is shown in pink. Unchanged expression is shown in gray. Number of genes with increasing expression during differentiation is increased for genes downregulated in FBXO11 KO neurons. down = downregulated, up = upregulated, not sig = expression not significantly changed, exp. = expression. " width="100%" height="100%">
Figure S7 A. At least 30 neurospheres per genotype (≥8 neurospheres per line) from three independent experiments were analyzed. Significance was calculated using a Student’s t test. (C) Representative images of immunofluorescence of FBXO11 WT, HET, and KO NPCs stained with antibodies against proliferation markers Ki-67 (red) and mitotic marker pHH3 (green) are shown. Images were taken on an AxioImager Z2 with a 20× objective. Scale bar, 100 μm. (D) Quantification of Ki67-positive cells among NPCs shows increased levels of Ki67-positive HET and KO cells. Quantification for individual lines can be found in